[Blood-borne infections in hemodialysis: facts and opinions].
The epidemiological impact of blood-borne infections (HCV, HBV and HIV) in dialysis is a major concern. In the past two decades the implementation of specific recommendations for prevention has been associated with a sharp reduction of the HBV and HCV incidence in this setting. Moreover, in recent years new therapeutic agents against these viruses were introduced, resulting in a marked improvement in clinical outcomes in subjects with normal kidney function. A collaborative effort between nephrologists and infectious disease specialists should be made to extend this improvement to chronic kidney disease patients.
Perboni
G
G
Unita' Operativa Complessa Malattie Infettive, Azienda Ospedaliera C. Poma, Mantova 46100, Italy. giorgio.perboni@poste.it
Costa
P
P
Scalzini
A
A
D000998:Antiviral Agents / Q000627:therapeutic use; D001782:Blood Donors; D017848:Blood-Borne Pathogens; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D015658:HIV Infections / Q000635:transmission; D006509:Hepatitis B / Q000635:transmission; D006526:Hepatitis C / Q000635:transmission; D006801:Humans; D007558:Italy / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000628:therapy; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects* / Q000401:mortality; D018570:Risk Assessment
D000998:Antiviral Agents